• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Integrating Cancer Biomarkers into Clinical Practice is the Goal for Development Companies As Well As Clinicians

Posted on: Friday, 4 May 2007, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c55948) has announced the addition of the new Decision Resources report "Cancer Biomarkers: New Tools for Transforming Cancer Management" to their offering.

Although novel cancer biomarkers are reported on a weekly basis, only a handful are actually translated into fully validated diagnostic tools. To fully understand the process, we explore the current status of the cancer biomarker field, roadblocks that slow the development process, the cancer biomarker pipeline, as well as the outlook for integrating cancer biomarkers into clinical practice. We also profile select companies that are actively pursuing cancer biomarker discovery and development.

Get the Answers You Need to Shape Your Strategy

Companies are utilizing cutting-edge technologies to develop, validate, and implement cancer biomarkers for clinical use. What impediments still exist to incorporating promising research into clinical practice? Which biomarkers show the most promise for approval?

Integrating cancer biomarkers into clinical practice is the goal for development companies as well as clinicians.

What are the economic challenges to approval? How can regulatory oversight drive approval and adoption of new technologies? No one company or agency has the necessary scope or expertise to drive the discovery, development, and implementation of sensitive and specific biomarkers. Which alliances show the greatest synergy in bringing valid biomarkers to market? Which shared technologies are driving the most encouraging development?

Scope

Trends in Cancer Biomarker Development: Biomarker discovery and validation, as well as the role of the diagnostics.

Emerging Biomarkers in Select Cancers: Bladder, breast, colorectal, lung, pancreatic, prostate, and renal cell.

Profiles of Select Cancer Biomarker Companies: Biomarker Technologies, Ciphergen, Claros Diagnostics, Epigenomics, Exagen Diagnostics, Genesis Genomics, Health Discovery Corporation, Ipsogen, Matritech, Miraculins, Orion Genomics, Phenomenone Discoveries, Power3 Medical Products, Upstream Biosciences.

Challenges: How strategic alliances and interdisciplinary involvement will need to drive development and implementation of emerging biomarker technologies.

Areas covered:

- Strategic Considerations - Stakeholder Implications - Overview - Traditional Use of Biomarkers in Cancer Management - Trends in Cancer Biomarker Development - Biomarker Discovery - Clinical Validation of Cancer Biomarkers - Ciphergen - Miraculins - Panacea Pharmaceuticals - Biomarker Technologies - Engagement of Diagnostics Industry - Recent Advances in Detection Technologies - Image-Based Biomarkers - The "omics" Platforms - Nanodiagnostics - Applications of Cancer Biomarkers - Transformation of Clinical Trial Design - Genetic Predisposition - Screening and Early Detection of Cancer - Diagnosis and Prognosis - Treatment Selection and Response - Recurrence - Emerging Biomarkers in Select Cancers - Bladder Cancer - Breast Cancer - Colorectal Cancer - Lung Cancer - Pancreatic Cancer - Prostate Cancer - Renal Cell Carcinoma - Roadblocks to Integrating Cancer Biomarkers into Clinical Practice - Technical Challenges - Lack of a Centralized Database - Economic Challenges - Regulatory Oversight - Current Activities of Cancer Biomarker Companies - Biomarker Technologies - Ciphergen - Claros Diagnostics - Epigenomics - Exagen Diagnostics - Genesis Genomics - Health Discovery Corporation - Ipsogen - Matritech - Miraculins - Orion Genomics - Phenomenome Discoveries - Power3 Medical Products - Upstream Biosciences - SPECTRUM Biomarkers and Diagnostics 3-3 - Cancer Biomarkers

For more information visit http://www.researchandmarkets.com/reports/c55948

Source: Business Wire

More News in this Category